糖尿病与个体化抗血小板治疗在PCI后冠心病患者中的结局
本研究基于PATH-PCI试验,比较血小板功能检测(PFT)引导的个体化双联抗血小板治疗(DAPT)在伴或不伴糖尿病的稳定冠心病(CAD)行经皮冠状动脉介入(PCI)患者中的结局。结果显示,个体化治疗组在糖尿病和非糖尿病患者中均显著降低缺血事件发生率,且不增加出血事件。
要点
- 无论是否合并糖尿病,个体化DAPT均未显著增加出血事件。
核心结论
- PFT引导的个体化抗血小板治疗可降低稳定CAD合并或不合并糖尿病PCI患者的缺血事件,且不增加出血。
研究设计与样本
- PATH-PCI随机对照试验纳入2285例稳定CAD行PCI患者,随机分为个体化抗血小板治疗组或标准抗血小板治疗组,按糖尿病状态分析结局。
临床怎么用
- 对于稳定CAD行PCI的患者,无论是否合并糖尿病,可考虑采用PFT(如PL-12)引导的个体化DAPT以降低缺血事件而不增加出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: A personalized antiplatelet therapy guided by a novel platelet function testing (PFT), PL-12, is considered an optimized treatment strategy in stable coronary artery disease (CAD) patients undergoing percutaneous coronary intervention (PCI). However, the safety and efficacy of any dual-antiplatelet therapy (DAPT) strategy may differ in relation to diabetes status. OBJECTIVE: The aim of this study was to compare the outcomes of PFT-guided personalized DAPT in stable CAD patients with and without diabetes mellitus. METHODS: The PATH-PCI trial randomly assigned 2285 stable CAD patients to either personalized antiplatelet therapy or standard antiplatelet treatment. We investigated the association and interaction of diabetes on clinical outcomes across 2 treatment groups. RESULTS: We did not find a significant difference between the personalized group and the standard group in net adverse clinical events in either diabetes patients (10.3% vs 13.4%, P = .224) or in the nondiabetic group (3.1% vs 5.0%, P = .064). In diabetes patients (n = 646, 28.3%), the overall ischemic event rates were significantly low (6.8% vs 11.3%, HR = 0.586, 95% CI, 0.344-0.999, P = .049) and the bleeding event rates did not differ between the 2 groups (3.5% vs 3.3%, HR = 1.066, 95% CI, 0.462-2.458, P = .882). Similarly, in nondiabetic patients, the overall ischemic event rates were significantly low (1.8% vs 4.2%, HR = 0.428, 95% CI, 0.233-0.758, P = .006) and the bleeding event rates did not differ between the 2 groups (1.6% vs 0.9%, HR = 1.802, 95% CI: 0.719-4.516, P = .209). CONCLUSION: The present study suggests that personalized antiplatelet therapy according to PFT can reduce ischemic events but not increase bleedings in stable CAD patients with or without diabetes who have undergone PCI.
引用
- Zheng YY, Wu TT, Yang Y, et al. Diabetes and Outcomes Following Personalized Antiplatelet Therapy in Coronary Artery Disease Patients Who Have Undergone PCI. J Clin Endocrinol Metab. 2022. PMID: 34410414. doi:10.1210/clinem/dgab612
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。